Trial Profile
A Phase II Study of RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Pasireotide (Primary)
- Indications Uveal melanoma
- Focus Therapeutic Use
- 29 Jan 2018 According to results published in the Melanoma Research, the study was terminated due to poor accrual.
- 29 Jan 2018 Status changed from active, no longer recruiting to discontinued, according to results published in the Melanoma Research.
- 16 Jun 2016 Status changed from active, no longer recruiting to completed.